Jensen L, et al. - The researchers used Child-Pugh criteria to examine whether the pharmacokinetic characteristics of semaglutide were altered in subjects with hepatic impairment vs those with normal hepatic function. They found no influence of hepatic impairment on semaglutide exposure, implying that no dose adjustment could be needed in patients with hepatic impairment. As per findings, semaglutide was well tolerated and there were no unexpected safety issues.